• Institute of Good Manufacturing Practices India
  • Global accredited training & certification provider
  • Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India
  • Approved Training Institute of Food Safety and Standards Authority of India (FSSAI)
  • Recognized by Department of Industrial Policy & Promotion, Ministry of Commerce & Industry, Government of India
  • An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India
  • Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh
  • Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC) set up by National Skill Development Corporation (NSDC)
  • Conferred with QUALITY COUNCIL OF INDIA (QCI) – D.L. SHAH NATIONAL QUALITY AWARD & ASSOCHAM Services Excellence Award 2017

Trusted by organizations & training participants in over 30 countries
Training | Certification | Education | Research


Phase 1 Clinical Trial initiated for APVO210

Updated: 20 March 2019

A novel Bi-specific antibody, APVO210 developed by Aptevo Therapeutics has been developed to treat Inflammatory and Autoimmune disorders. As per the officials of the firm, the Phase 1 clinical trials for the bi-specific antibody have been initiated. The major aim of the biotechnology company, Aptevo Therapeutics Inc. is to develop novel hematology, autoimmune and oncology therapeutics.

The Phase 1 trial is a double-blind, randomized, single and multiple ascending dose study of APVO210, placebo-controlled study being conducted in Australia currently. The pharmacodynamics, pharmacokinetics, tolerability and safety of APVO210 are being evaluated in healthy subjects.

The two stages for the study will include assessment of single ascending dose and multiple ascending dose of APVO210. Doses will be given either biweekly or weekly till 4 weeks through intravenous infusion. 64 subjects for first stage and 40 subjects for second stage are expected to enroll for the study.

Reporting of results for first stage in third quarter of 2019 followed by reporting safety data by last quarter of 2019 is anticipated by Aptevo.